ATRY Atrys Health, S.A.

2.819USD2.570 EUR · BME-1.72%Mkt Cap: 214.00M USDP/E: —

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medic…

Key Statistics

Company
Market Cap214.00M USD
Enterprise Value328.17M USD
Revenue (TTM)161.97M USD
Gross Profit67.28M USD
Net Income (TTM)-110.00M USD
Revenue/Share2.14 USD
Last Price2.819 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees763
CountryES
SectorHealthcare
IndustryBiotechnology
ISINES0105148003
Valuation
P/E (Trailing)—
P/E (Forward)20.04
PEG—
EV/EBITDA1201.63
EV/Revenue2.03
P/S1.31
P/B1.31
EPS (TTM)-0.69 USD
EPS (Forward)0.14 USD
52W Range
2.53430% of range3.499
52W High3.499 USD
52W Low2.534 USD
Profitability
Gross Margin43.51%
Oper. Margin-5.22%
EBITDA Margin0.17%
Profit Margin-71.13%
ROE-66.05%
ROA-20.30%
ROIC-1.43%
ROCE-2.82%
Growth
Revenue Growth9.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.71M USD
CapEx (TTM)13.73M USD
FCF Margin8.65%
FCF Yield6.55%
Net Debt115.81M USD
Net Debt/EBITDA424.04
Net Debt/FCF8.26
Balance Sheet
Debt/Equity1.70
Current Ratio0.47
Quick Ratio0.39
Book Value/Sh2.13 USD
Cash/Share0.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.411 USD
Upside (mean)+92.0%
Target Range4.716 USD – 6.032 USD
4.716+92.0% to mean6.032
# Analysts3
Ownership
Shares Out.75.92M
Float42.47M
Insiders56.77%
Institutions11.07%
Technical
SMA 502.918 (-3.4%)
SMA 2002.965 (-4.9%)
Beta0.53
S&P 52W Chg12.00%
Avg Vol (30d)32.65K
Avg Vol (10d)44.70K
Technical Indicators
RSI (14)42.0
MACD-0.0030
MACD Signal0.0032
MACD Hist.-0.0062
BB Upper2.985 USD
BB Middle2.895 USD
BB Lower2.804 USD
BB Width6.25%
ATR (14)0.0983 USD
Vol Ratio (20d)2.15x

About Atrys Health (BME: ATRY)

›

Atrys Health (BME: ATRY) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 763 employees.

The shares were at 2.570 EUR on 19 November 2026, down 4.1% over 52 weeks. Its 52-week range is 2.310 EUR to 3.190 EUR: the price is 19.4% below the high and 11.3% above the low.

Its market capitalisation is 195.11M EUR.

Atrys Health reports return on equity of -66.0%, an operating margin of -5.2% and revenue up 9.4% year over year.

Its debt exceeds its cash by 105.59M EUR, a debt-to-equity ratio of 1.70. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 4.933 EUR is 92.0% above the current price.